• Recruiting

NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM

Updated: Sep 24

DETER-SMM

EAA173

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

DETER-SMM smoldering myeloma study ecog-acrin

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma


This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.


Sponsor

ECOG-ACRIN Cancer Research Group


Collaborator

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT03937635

Official Title: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

First Posted : May 6, 2019

Click here for details on ClinicalTrials.gov


EAA173 / DETER-SMM Home Page - ECOG-ACRIN Cancer Research Group

 

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information

 

Biological: Daratumumab

Drug: Dexamethasone

Drug: Lenalidomide

Other: Quality-of-Life Assessment

Other: Questionnaire Administration

 

- Connecticut: Yale University New Haven

- Georgia: Emory University Atlanta

- Minnesota: Mayo Clinic Rochester Minnesota

- Texas: The University of Texas MD Anderson Cancer Center Houston

 

Locations

United States, Alaska

United States, Arizona

United States, Arkansas

United States, California

United States, Colorado

United States, Connecticut

United States, Florida

United States, Georgia

United States, Idaho

United States, Illinois

United States, Indiana

United States, Iowa

United States, Kansas

United States, Kentucky

United States, Louisiana

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Missouri

United States, Montana

United States, Nebraska

United States, Nevada

United States, New Jersey

United States, New York

United States, North Carolina

United States, North Dakota

United States, Ohio

United States, Oklahoma

United States, Oregon

United States, Pennsylvania

United States, Rhode Island

United States, South Carolina

United States, South Dakota

United States, Texas

United States, Utah

United States, Virginia

United States, Washington

United States, West Virginia

United States, Wisconsin

United States, Wyoming

 

ECOG Trials - Currently Recruiting


NCT04566328: Phase 3 - EAA181 / EQUATE - Testing the Use of Combination Therapy in NDMM

Click here for details


NCT03937635: Phase 3 - EAA173 / DETER-SMM - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma

Click here for details


NCT03941860: Phase 3 - EAA171 / OPTIMUM - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma

Click here for details


NCT02465060: Phase 2 - EAY131 / NCI-MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Click here for details




Posts Archive